European Commission approves Pluvicto™
European Commission Approves Pluvicto for PSMA-Positive mCRPC OncLive, Dec 14, [...]
Dr Acosta’s testimonial : A journey living with prostate cancer
Discover Dr. Fernando Acosta’s treatment journey with radiotheranostics in his [...]
Lu-177-PSMA-617 approved by FDA for prostate cancer patients
Novartis has obtained US Food and Drug Administration (FDA) marketing [...]
Novel Radioligand Proven Superior for Metastatic Prostate Cancer
Novel Radioligand Therapy Proven Superior for Metastatic Prostate Cancer Patients [...]
Get more insight from the NOBLE Registry Website
Revealing the website of the NOBLE Registry : get more [...]
Q&A: How a new imaging tool helps to better stage prostate cancer
Q&A by Doctor Jeremie Calais on how PSMA PET imaging [...]
FDA for Lu-177-PSMA-617 for mCRPC treatment
Targeted Oncology, Sarah Karlovitch, June 17, 2021 The FDA has [...]
Drugmakers push into radio pharmaceuticals
Dolgin, E. Drugmakers go nuclear, continuing push into radiopharmaceuticals. Nat Biotechnol 39, 647–649 [...]
NOBLE: Tc-99m-iPSMA SPECT shows promising results
Promising results following the initial experience using Tc-99m-iPSMA led by [...]
Asco 2021 justifies Novartis’s radioligand Vision
Evaluate Vantage, Jacob Plieth, June 3, 2021 177Lu-PSMA-617 significantly improves [...]